Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oncology

Pathology & Testing: Understanding Your Reports and MRD

At a Glance

Minimal residual disease (MRD) testing is the most crucial part of tracking Acute Lymphoblastic Leukemia (ALL) treatment. While standard tests confirm a diagnosis by finding at least 20% blasts, highly sensitive MRD tests detect hidden cancer cells to show if your treatment is truly working.

Understanding your pathology and testing reports is essential for tracking your progress. These documents may look like a different language, but they contain the “blueprint” of your leukemia and the “scoreboard” of how well treatment is working [1][2].

How ALL is Diagnosed

To officially diagnose Acute Lymphoblastic Leukemia (ALL), doctors perform a bone marrow aspiration and biopsy [1]. They look for two main things:

  1. Blast Count: At least 20% of the cells in your bone marrow must be “blasts” (immature leukemia cells) [1][3]. (Note: If the blast count is under 20% but the biology is identical, the diagnosis is called Lymphoblastic Lymphoma, or LBL).
  2. Lineage: Using a test called flow cytometry, doctors identify if these blasts are B-cells or T-cells. They look for specific markers (like CD19, CD10, or CD3) that act like “ID badges” for the cancer cells [2][4].

The Blueprint: Cytogenetics and Genomic Profiling

Once the diagnosis is made, the lab digs deeper into the DNA of the cancer cells. You will see these tests on your reports:

  • Karyotyping & FISH: These tests look for large-scale chromosomal changes, like the Philadelphia chromosome (Ph+) [5][6].
  • Next-Generation Sequencing (NGS): This is a high-tech “spell-check” that scans the DNA for tiny mutations or “Ph-like” patterns that standard tests might miss [7][8].
  • Why it matters: These results determine your risk stratification. If “high-risk” markers (like KMT2A or IKZF1 deletions) are found, your doctor may recommend more intensive therapy or a stem cell transplant early on [9][10].

The Scoreboard: Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) is arguably the most important term you will hear throughout your journey [11][12].

Think of leukemia like a forest fire. After the main fire is put out, a few small embers may still be smoldering underground. You can’t see them from a distance, but they could restart the fire later. MRD refers to these “leukemic embers”—tiny amounts of cancer that remain after treatment [11][13].

  • Sensitivity: Standard microscopes can only see leukemia if it makes up about 5% of your cells. MRD tests (using flow cytometry or NGS) are much more powerful, able to find one leukemia cell among 10,000 to 1,000,000 healthy cells [14][15].
  • Prognosis: Being MRD-negative (no detectable embers) at key time points, such as the end of the first month of treatment (Induction), is a very strong sign that the treatment is working [16][13].
  • Guiding Treatment: If you are MRD-positive, your doctor might “intensify” your treatment or add new drugs (like blinatumomab) to put out those remaining embers before they can cause a relapse [17][16].

Reading Your Report: Key Terms to Look For

Term What it Means
Blasts Immature, cancerous white blood cells.
Morphologic Remission Less than 5% blasts; the marrow looks “clean” under a standard microscope.
MRD-Negative No leukemia detected even with highly sensitive tests.
Karyotype/Cytogenetics The map of your chromosomes (e.g., t(9;22) is the Philadelphia chromosome).
Ploidy The total number of chromosomes; “high hyperdiploidy” (having 51-65 chromosomes) is often a favorable sign [18].

By understanding these terms, you can better engage with your medical team and understand the “why” behind your treatment plan [15].

Common questions in this guide

What percentage of blasts is required for an ALL diagnosis?
To officially be diagnosed with acute lymphoblastic leukemia, your bone marrow must contain at least 20% blasts, which are immature leukemia cells. If the blast count is lower but the cellular biology is identical, the diagnosis is called lymphoblastic lymphoma.
What does flow cytometry do in a leukemia diagnosis?
Flow cytometry is a test that identifies specific markers on the surface of your cancer cells. Doctors use it to determine if your leukemia is made up of B-cells or T-cells, acting like an ID badge that helps guide your treatment plan.
What is Minimal Residual Disease (MRD)?
Minimal residual disease, or MRD, refers to the tiny amount of leukemia cells that may remain in your body after treatment. Even if your bone marrow looks completely clear under a standard microscope, highly sensitive MRD tests can find these hidden cancer cells.
What does it mean to be MRD-negative?
Being MRD-negative means that highly sensitive tests could not find any remaining leukemia cells in your bone marrow. Reaching MRD-negative status after your first month of treatment is a very strong sign that your therapy is working.
How do MRD test results affect my leukemia treatment?
Your MRD results directly guide your next steps. If your tests show you are MRD-positive, your doctor may recommend intensifying your therapy or adding targeted drugs to eliminate the remaining leukemia cells and help prevent a relapse.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was the exact percentage of 'blasts' in my initial bone marrow sample?
  2. 2.What was my MRD status at the end of the first month (induction), and what sensitivity level was used for the test?
  3. 3.Does my pathology report show any 'high-risk' deletions, such as IKZF1, that we should be aware of?
  4. 4.Will my future treatment be adjusted (intensified or reduced) based on my current MRD results?
  5. 5.Are there any clinical trials or targeted drugs available specifically for my leukemia's genetic profile or MRD status?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Fifth Edition of the World Health Organization Classification of Tumors of the Hematopoietic and Lymphoid Tissues: Acute Lymphoblastic Leukemias, Mixed-Phenotype Acute Leukemias, Myeloid/Lymphoid Neoplasms With Eosinophilia, Dendritic/Histiocytic Neoplasms, and Genetic Tumor Syndromes.

    Choi JK, Xiao W, Chen X, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2024; (37(5)):100466 doi:10.1016/j.modpat.2024.100466.

    PMID: 38460674
  2. 2

    Aberrant immunophenotypes in acute lymphoblastic leukemia.

    Cuéllar-Mendoza ME, Chávez-Sánchez FR, Dorantes-Acosta E, et al.

    Boletin medico del Hospital Infantil de Mexico 2020; (77(6)):287-292 doi:10.24875/BMHIM.20000171.

    PMID: 33186349
  3. 3

    The origin of relapse in pediatric T-cell acute lymphoblastic leukemia.

    Vicente C, Cools J

    Haematologica 2015; (100(11)):1373-5 doi:10.3324/haematol.2015.136077.

    PMID: 26521295
  4. 4

    CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.

    Angelova E, Audette C, Kovtun Y, et al.

    Haematologica 2019; (104(4)):749-755 doi:10.3324/haematol.2018.205252.

    PMID: 30361418
  5. 5

    Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients.

    Zak T, Gao J, Behdad A, et al.

    Leukemia & lymphoma 2022; (63(13)):3200-3207 doi:10.1080/10428194.2022.2113524.

    PMID: 35995457
  6. 6

    A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings.

    Parihar M, Singh MK, Islam R, et al.

    Pediatric blood & cancer 2018; (65(12)):e27366 doi:10.1002/pbc.27366.

    PMID: 30168245
  7. 7

    PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

    Gu Z, Churchman ML, Roberts KG, et al.

    Nature genetics 2019; (51(2)):296-307 doi:10.1038/s41588-018-0315-5.

    PMID: 30643249
  8. 8

    Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.

    Jeha S, Choi J, Roberts KG, et al.

    Blood cancer discovery 2021; (2(4)):326-337 doi:10.1158/2643-3230.BCD-20-0229.

    PMID: 34250504
  9. 9

    Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements.

    Tanasi I, Ba I, Sirvent N, et al.

    Blood 2019; (134(16)):1351-1355 doi:10.1182/blood.2019001244.

    PMID: 31434701
  10. 10

    IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature.

    Ruiz-Delgado GJ, Cantero-Fortiz Y, León-Peña AA, et al.

    Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion 2016; (68(4)):210-4.

    PMID: 27623040
  11. 11

    Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.

    Short NJ, Jabbour E, Albitar M, et al.

    American journal of hematology 2019; (94(2)):257-265 doi:10.1002/ajh.25338.

    PMID: 30394566
  12. 12

    Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia.

    Hein K, Short N, Jabbour E, Yilmaz M

    Blood and lymphatic cancer : targets and therapy 2022; (12()):7-16 doi:10.2147/BLCTT.S270134.

    PMID: 35340663
  13. 13

    Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience.

    Ibrahim RI, Saeed AM

    Asian Pacific journal of cancer prevention : APJCP 2022; (23(5)):1647-1651 doi:10.31557/APJCP.2022.23.5.1647.

    PMID: 35633549
  14. 14

    SOHO State of the Art Updates and Next Questions | Next Questions: Acute Lymphoblastic Leukemia.

    Senapati J, Kantarjian H, Haddad FG, et al.

    Clinical lymphoma, myeloma & leukemia 2024; (24(6)):333-339 doi:10.1016/j.clml.2023.12.013.

    PMID: 38195323
  15. 15

    Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.

    Issa GC, Kantarjian HM, Yin CC, et al.

    Cancer 2017; (123(3)):459-467 doi:10.1002/cncr.30376.

    PMID: 27696391
  16. 16

    Who Should Receive an Allogeneic Transplant in First Complete Remission?

    Ribera JM, Genescà E, Ribera J

    Clinical lymphoma, myeloma & leukemia 2020; (20 Suppl 1()):S48-S51 doi:10.1016/S2152-2650(20)30459-6.

    PMID: 32862866
  17. 17

    FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.

    Jen EY, Xu Q, Schetter A, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(2)):473-477 doi:10.1158/1078-0432.CCR-18-2337.

    PMID: 30254079
  18. 18

    CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients.

    Xu N, Li YL, Zhou X, et al.

    Journal of Cancer 2015; (6(11)):1114-20 doi:10.7150/jca.11959.

    PMID: 26516359

This page explains Acute Lymphoblastic Leukemia pathology and testing terminology for educational purposes. Your hematologist or oncologist is the best source for interpreting your specific lab results and MRD status.

Get notified when new evidence is published on Acute lymphoblastic leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.